Novel eRF3a degrader enhances gentamicin-induced premature termination codon readthrough in epidermolysis bullosa.

Kathleen L Miao, Brandon Levian, Yingping Hou, Ryan Huynh, Kate Zheng, Mei Chen

Abstract read

In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Turning premature stop codons into therapeutic opportunities.Molecular therapy. Nucleic acids · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kathleen L MiaoDepartment of Dermatology, The Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Brandon LevianDepartment of Dermatology, The Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Yingping HouDepartment of Dermatology, The Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Ryan HuynhDepartment of Dermatology, The Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Kate ZhengDepartment of Dermatology, The Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Mei ChenDepartment of Dermatology, The Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB) are severe blistering skin disorders caused by mutations in genes encoding type VII collagen (

Indexed as

epidermolysis bullosaextracellular matrixgenetic diseasesMT: Delivery Strategiesreadthrough therapyskin

Identifiers

PMID41210582

DOI10.1016/j.omtn.2025.102741

PMCPMC12594917

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.